irinotecan has been researched along with Acute Kidney Injury in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akiyama, Y; Fujita, K; Kato, Y; Kawara, K; Kitamura, M; Kunishima, M; Masuo, Y; Okumura, H; Sasaki, Y; Shimada, K; Sunakawa, Y; Suzuki, H; Watanabe, Y | 1 |
| Adachi, M; Horichi, N; Ichikawa, I; Imai, T; Kashiwabara, Y; Kiuchi, Y; Kogo, M; Koichi, K; Murayama, J; Saito, Y | 1 |
| Crawford, J; Garst, J; Persons, DA; Vollmer, R | 1 |
3 other study(ies) available for irinotecan and Acute Kidney Injury
| Article | Year |
|---|---|
Increased Plasma Concentrations of Unbound SN-38, the Active Metabolite of Irinotecan, in Cancer Patients with Severe Renal Failure.
Topics: Acute Kidney Injury; Antineoplastic Agents, Phytogenic; Camptothecin; Humans; Irinotecan; Kidney; Models, Biological; Neoplasms; Protein Binding | 2016 |
[Clinical pathway based on evidence-based medicine (EBM) for chemotherapy for lung cancer].
Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Critical Pathways; Etoposide; Evidence-Based Medicine; Female; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Vomiting | 2004 |
Tumor lysis syndrome and acute renal failure after treatment of non-small-cell lung carcinoma with combination irinotecan and cisplatin.
Topics: Acute Kidney Injury; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Irinotecan; Lung Neoplasms; Tumor Lysis Syndrome | 1998 |